He doesn't discover the drugs. He gets them across the finish line. Newleos hired him to revive four molecules Roche left for dead - and to do it the way he has done it twice before: build the team, run the trial, ring the IPO bell.
Newleos Therapeutics did not invent its science. It rescued it. Four neuropsychiatric compounds that Roche developed, then discontinued, now sit at the center of a Boston biotech with $93.5 million in fresh capital and a plan to prove the world's largest pharma company wrong. In October 2025, the board handed the wheel to Timothy Noyes.
The choice was not subtle. Noyes has spent three decades doing exactly one thing well: taking a molecule that already exists and marching it toward the next clinical milestone. He has done it with kidney drugs, vascular biologics, and an inhaled treatment for pulmonary hypertension. Now the organ is the brain, and the targets are anxiety, neurodevelopmental disorders, addiction, and social withdrawal.
"The company is at a pivotal inflection point," he said on joining, "translating strong science into clinical momentum across programs that could redefine how anxiety and related disorders are treated." It is the kind of sentence a lot of CEOs say. The difference is that Noyes has the receipts.
He succeeds David Donabedian, the founding CEO who built Newleos out of the Longwood Fund and then stepped into an advisory seat. Christoph Westphal, the serial biotech founder, chairs the board. The investors - Goldman Sachs Alternatives, Novo Holdings, Longwood, DCVC Bio, Arkin - wrote checks against the science. They hired Noyes to run it.
"I am thrilled to join Newleos. The company is at a pivotal inflection point, translating strong science into clinical momentum across programs that could redefine how anxiety and related disorders are treated."
Read the resume and you notice the through-line. Hypertension and heart failure at Merck, where he sold Vasotec and Prilosec and learned the commercial side of medicine. Kidney disease at GelTex, where he led the launch of Renagel for patients on dialysis. When Genzyme bought GelTex, he ran its Renal Division as president.
Then the CEO seats. Proteon Therapeutics in 2006, where he built a team that took the company public and pushed a blood-vessel biologic from preclinical work all the way to Phase 3. Aerovate Therapeutics in 2021, another IPO, another lead program - this time inhaled imatinib for pulmonary arterial hypertension - carried into a global Phase 2/3 trial.
Five therapeutic areas. One repeated motion: inherit a promising asset, assemble the people, raise the money, generate the data. Newleos is the cleanest expression of that pattern yet, because the assets arrived pre-validated by Roche's own years of work. As Bolognani put it, that prior development "enables faster data generation." Noyes's entire career has been an argument that speed and discipline beat invention.
Newleos licensed four discontinued Roche compounds, each aimed at a different corner of neuropsychiatry. This is the inheritance Noyes was hired to develop.
A GABAA-γ1 selective positive allosteric modulator targeting amygdala-specific GABA receptors.
A GABA modulator for cognitive impairment in rare conditions, including dup15q11 syndrome.
A TAAR1 agonist being developed for substance-use disorders.
A V1a receptor antagonist aimed at social anxiety and related withdrawal.
Because the molecules came pre-developed, Newleos targets Phase 2 readouts across all four programs by fall 2027. The bars below sketch relative development maturity at the company's debut - a reminder that Noyes isn't starting from zero.
Bars are illustrative of relative program maturity, not exact trial endpoints. Company guidance: Phase 2 data across programs anticipated by fall 2027.
Newleos came out of the Longwood Fund, where Donabedian was a partner. The co-founders read like a Boston biotech all-star list: Christoph Westphal, Miguel Sobral, Rob Hadfield. Westphal, the executive chair, has founded a string of companies; when Noyes was hired, he pointed to exactly the thing Noyes is known for - company building and advancing clinical programs.
The $93.5 million round was oversubscribed and led by Goldman Sachs Alternatives, with Novo Holdings, Longwood, DCVC Bio, and Arkin Bio Capital alongside. That is patient, deep-pocketed capital, the kind that expects a CEO who has navigated public markets before. Noyes has rung the IPO bell twice. The board's bet is that the third company is the one where the science was de-risked before he ever walked in.